SLC6A4 and pulmonary arterial hypertension: Since increased 5-HT potentiates the development of PAH in rodents[6] and likely in humans[7], the simplest explanation for these data is through direct effect on signaling through 5-HTT, rather than by impact on 5-HT itself.